TWST Stock Overview
Manufactures and sells synthetic DNA-based products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Twist Bioscience Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.23 |
| 52 Week High | US$60.90 |
| 52 Week Low | US$23.07 |
| Beta | 1.78 |
| 11 Month Change | 4.01% |
| 3 Month Change | -3.98% |
| 1 Year Change | 72.47% |
| 33 Year Change | -55.54% |
| 5 Year Change | 77.21% |
| Change since IPO | 201.64% |
Recent News & Updates
Twist Bioscience: A Post-Earnings Assessment
Nov 18Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Nov 08Recent updates
Twist Bioscience: A Post-Earnings Assessment
Nov 18Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Nov 08Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Sep 25
Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues
Aug 20Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Aug 04Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock
Jul 26We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth
Jun 10Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth
May 04Twist Bioscience: NGS Is Taking Off
May 03Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Feb 27Twist Bioscience: Strong Performance In A Soft Market
Feb 07Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet
Jan 31We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Dec 18Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07Shareholder Returns
| TWST | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.5% | 2.5% | 2.2% |
| 1Y | 72.5% | 16.1% | 31.6% |
Return vs Industry: TWST exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: TWST exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| TWST volatility | |
|---|---|
| TWST Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TWST has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TWST's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 923 | Emily Leproust | www.twistbioscience.com |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
Twist Bioscience Corporation Fundamentals Summary
| TWST fundamental statistics | |
|---|---|
| Market cap | US$2.51b |
| Earnings (TTM) | -US$208.73m |
| Revenue (TTM) | US$312.97m |
8.0x
P/S Ratio-12.0x
P/E RatioIs TWST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TWST income statement (TTM) | |
|---|---|
| Revenue | US$312.97m |
| Cost of Revenue | US$179.63m |
| Gross Profit | US$133.35m |
| Other Expenses | US$342.08m |
| Earnings | -US$208.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.52 |
| Gross Margin | 42.61% |
| Net Profit Margin | -66.69% |
| Debt/Equity Ratio | 0% |
How did TWST perform over the long term?
See historical performance and comparison